Recruiting at 1 site Phase 4 COVID-19

COVID-19 study: Primary Cohort

Official title A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

ClinicalTrials.gov ID: NCT06008860

What this study is testing

What is Astepro (azelastine) nasal spray?

This is an investigational nasal spray being studied to see if it can help treat COVID-19. It is designed to block histamine and reduce inflammation in the nose.

Also referred to as azelastine.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study checks if Astepro nasal spray works to treat early SARS-CoV-2 infection.
Who it's for
Adults with an early SARS-CoV-2 infection.
What's involved
Participants will use Astepro nasal spray and take part in a pilot trial to see if it is effective.
Time commitment
The source text does not specify the duration or visit schedule.
  • Phase 4: studies an already-approved treatment
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older. Healthy volunteers may be eligible.

You may be able to join if

  • 18 and up
  • Ability to consent
  • Have a Covid-19 positive saliva sample prior to the start of treatment
  • Ability to follow the study instructions and adhere to the study procedures
  • Ability to provide every other day saliva samples throughout the study period 10 days, and report symptoms

You likely can't join if

  • Women who are breastfeeding, pregnant, or who plan to become pregnant
  • Contradictions to intranasal azelastine (known hypersensitivity)
  • Use of other Covid-19 treatments (steroids, convalescent plasma, therapeutic antibodies, etc.)
  • Intranasal, corticosteroid, immunomodulator, or other medication use which can change the effect of Astepro.
  • Prior Covid infection greater than 5 and less than 30 days before enrollment
  • people who have been involved with any other research study within the last 30 days.
See the full eligibility criteria
Who can join
  • 18 and up
  • Ability to consent
  • Have a Covid-19 positive saliva sample prior to the start of treatment; or positive rapid antigen test at home confirmed via first COVID-19 positive saliva sample
  • Ability to follow the study instructions and adhere to the study procedures
  • Ability to provide every other day saliva samples throughout the study period 10 days, and report symptoms
  • people that have been vaccinated for Covid-19
  • Ability to consent
  • Ability to follow the study instructions and report side effects
  • Ability to provide saliva samples throughout the study period
  • people that have been vaccinated for Covid-19.
What rules you out
  • Women who are breastfeeding, pregnant, or who plan to become pregnant
  • Contradictions to intranasal azelastine (known hypersensitivity)
  • Use of other Covid-19 treatments (steroids, convalescent plasma, therapeutic antibodies, etc.)
  • Intranasal, corticosteroid, immunomodulator, or other medication use which can change the effect of Astepro.
  • Prior Covid infection greater than 5 and less than 30 days before enrollment
  • people who have been involved with any other research study within the last 30 days.
  • A prior hypersensitivity to olopatadine (Patanase), diphenhydramine, hydroxyzine. people that have not been vaccinated for Covid-19.
  • Prior Covid infection less than 30 days or greater 5 days prior to enrollment in study
  • Use of other Covid-19 treatments
  • Having a positive rapid home or PCR COVID test prior to the positive test for the primary cohort subject they're associated with
  • Involved with any other research study within the last 30 days
  • people that have not been vaccinated for Covid-19.

The study team makes the final eligibility decision.

Where it is enrolling

  • Chicago, Illinois, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.